Fundraising Fox

Bali Muralidhar

Investor

Managing Partner at Abingworth

London

Writes $15M – $30M checks Β· typically $22.5M

About

Bali Muralidhar has more than 20 years of healthcare experience spanning venture investing, R&D, clinical practice, and teaching. At Abingworth he leads the transatlantic venture and clinical co-development investment teams and chairs the firm's investment committees. He previously was a senior partner at MVM Partners in London and a member of Bain Capital's healthcare deal team. He holds a degree in clinical medicine from the University of Oxford, practiced general surgery, and earned a PhD in translational cancer research from the University of Cambridge.

Invests in

BiotechHealthtech

Experience

  1. AbingworthGlobal Head of Life Sciencescurrent2026 β€” present
  2. AbingworthManaging Partner, Chief Investment Officercurrent2022 β€” present
  3. AbingworthManaging Partnercurrent2020 β€” presentLondon, United Kingdom
  4. AbingworthPartner2019 β€” 2020
  5. British Business BankNon Executive Directorcurrent2025 β€” presentLondon, United Kingdom
  6. MVM PartnersPartner2012 β€” 2019London, United Kingdom
  7. Bain CapitalAssociate2011 β€” 2012
  8. Bain & CompanyConsultant2008 β€” 2011
  9. University of Cambridge, Downing CollegeBye-Fellow2006 β€” 2008
  10. Medical Reseach CouncilResearcher2005 β€” 2008Translational Cancer Cell Unit - Cambridge University
  11. National Health ServiceClinical Fellow2004 β€” 2008Cambridge, United Kingdom

Education

  1. University of CambridgePhD, Cancer biology2005 β€” 2008
  2. University of OxfordBMBCh, Clinical medicine2001 β€” 2004
  3. University of CambridgeMA, Medical Science1998 β€” 2001

Skills & more

Strategy10Venture Capital34Private Equity14Healthcare13Biotechnology21Molecular Biology2Medicine4Cancer6Lifesciences5Business Strategy11Due Diligence9Corporate Development2
+4 moreStart-upsLife SciencesMergers & AcquisitionsPharmaceutical Industry

From Bali's professional profile.

Same school

Shared employers

Deals Β· 5

Allotera Therapeutics, Inc.Board seat

via Abingworth Β· filed Jul 2026 Β· $163M raise

AdvanCellBoard seat

via Abingworth Β· filed Jul 2026 Β· $315M raise

press β†—

Spruce Biosciences IncBoard seat

via Abingworth Β· filed Oct 2025 Β· $50M raise

WugenBoard seat

via Abingworth Β· filed Jul 2021 Β· $37.2M raise

Onkure Therapeutics IncBoard seat

via Abingworth Β· filed Dec 2020 Β· $94.8M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Abingworth

Network5

Investors connected to Bali in public investor directories β€” a warm-intro map.